Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01587300 · ClinicalTrials.gov registry record
Neuroblastoma Biology Study
A clinical trial of Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 17
- Study locations
NCT01587300 is a study of Neuroblastoma that is actively recruiting participants, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 1,000 participants, above the 228-participant average among 94 other Neuroblastoma trials with a reported enrollment target (339% higher). The trial reports 17 study locations across 13 states.
The verdict
NCT01587300, a study of Neuroblastoma, is actively recruiting participants, sponsored by New Approaches to Neuroblastoma Therapy Consortium.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 17
- Study locations
Study Summary
Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.
Conditions Studied
Study Locations (17)
California
- Children's Hospital Los Angeles - Los Angeles
- Lucille Salter Packer Children's Hospital, Stanford University - Palo Alto
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Texas
- University of Texas Southwestern - Dallas
- Cook Children's Medical Center - Fort Worth - Fort Worth
Colorado
- Children Hospital of Colorado - Aurora
Georgia
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus - Atlanta
Illinois
- University of Chicago, Comer Children's Hospital - Chicago
Massachusetts
- Children's Hospital Boston - Boston
Michigan
- C.S Mott Children's Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2011-07 |
| Est. Completion | 2099-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01587300
The ClinicalTrials.gov registry entry for NCT01587300 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 228-participant average among 94 other Neuroblastoma trials with a reported enrollment target (339% higher). The listed sponsor is New Approaches to Neuroblastoma Therapy Consortium, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 0 interventions.
NCT01587300 reports 17 study locations spanning 13 distinct geographic areas - top geographies include California, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT01587300 about?
NCT01587300 is a clinical study titled "Neuroblastoma Biology Study". Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and no...
What is the current status of trial NCT01587300?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2011-07. Estimated completion is 2099-12.
What conditions does trial NCT01587300 study?
This clinical trial studies the following conditions: Neuroblastoma.
Who is sponsoring clinical trial NCT01587300?
This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01587300 being conducted?
This trial has 17 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MCT for the Harvard/UCSF ROBIN Center
RECRUITING · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.